Understanding MASLD and Its Rising Prevalence in Singapore

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is characterized by excessive fat accumulation in the liver not caused by alcohol consumption. This condition affects the liver's ability to process fats, leading to inflammation and potentially severe complications like fibrosis, cirrhosis, and liver cancer. In Singapore, where rapid urbanization and dietary shifts have contributed to higher rates of obesity and diabetes, MASLD has become alarmingly common, impacting up to 40% of adults. This statistic underscores the urgency for innovative research, particularly from local universities like the National University of Singapore (NUS), which are at the forefront of tackling metabolic disorders.

The disease progresses silently: simple steatosis (fat buildup) can evolve into metabolic dysfunction-associated steatohepatitis (MASH), involving inflammation and hepatocyte ballooning, ultimately resulting in fibrosis—a scarring process where excessive collagen replaces healthy liver tissue. Early intervention is crucial, as fibrosis is a key prognostic marker for progression to end-stage liver disease. Current management relies on lifestyle changes such as weight loss, exercise, and diet, but no approved pharmacological treatments exist specifically for fibrosis reversal in MASLD.

A Groundbreaking Study Highlights GTPase as a Key Target

Recent research published in eLife has identified GTPase signaling pathways as a promising therapeutic target for halting early fibrosis in MASLD. Led by Professor Philipp Kaldis at Lund University Diabetes Centre, the international collaboration—including key contributions from NUS researchers like Associate Professor Hyungwon Choi for multi-omics analysis—analyzed liver biopsies from 109 obese individuals prior to bariatric surgery. Of these, 76 had early MASLD, allowing researchers to pinpoint molecular changes during the transition from steatosis to fibrosis.

The study revealed over 200 genes associated with fibrosis progression, with GTPases—small guanosine triphosphate-binding proteins that act as molecular switches regulating cell processes like cytoskeletal remodeling and signaling—emerging as the top enriched pathway. Specifically, Rho-GTPases such as RAC1, RAC2, and CDC42 showed upregulation, co-expressed with TGF-β signaling, a master regulator of fibrosis. "GTPase signaling emerged as the top enriched pathway involved in the transition from non-fibrotic steatosis to the onset of fibrosis," the authors noted.

Unpacking the Science: What Are GTPases and Their Role in Liver Fibrosis?

GTPases cycle between active (GTP-bound) and inactive (GDP-bound) states, controlled by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). In the liver, they orchestrate hepatic stellate cell (HSC) activation, where quiescent HSCs transform into myofibroblasts producing extracellular matrix proteins like collagen type I (COL1A1/2). TGF-β stimulation upregulates GEFs like DOCK2 and VAV1, promoting fibrosis.

Step-by-step, fibrosis develops as: (1) Fat accumulation triggers lipotoxicity; (2) Inflammation activates HSCs via TGF-β; (3) GTPases facilitate actin remodeling for matrix secretion; (4) Scar tissue impairs liver function. The Lund-NUS study used transcriptomics (RNA-seq) and metabolomics (LC-MS) on liver and plasma, validating findings in independent cohorts and mouse models.

• 27 GTPase genes positively associated with fibrosis grades.
• 10 genes negatively associated, suggesting regulators for therapeutic modulation.
• Integration showed GTPase networks overlapping with lipid metabolism and immunity pathways.

Experimental Evidence: GTPase Inhibitors Show Promise

In human HSC-like LX-2 cells, inhibitors targeting Rac1 (NSC23766) and Cdc42 (ML141) reduced pro-collagen secretion by 50-60% basally and 40% under TGF-β stimulation. qPCR confirmed lower COL1A1/2 expression. In 3D liver spheroids from MASH patients, GTPase genes were upregulated, partially restored by elafibranor (a PPARα/δ agonist). This multi-model approach—biopsies, cell lines, spheroids—strengthens causality.

"We have already proceeded with new studies where we study the mechanisms in detail to investigate whether we can establish a causal relationship," said Prof. Kaldis. For Singapore, where diabetes prevalence exceeds 11%, this could prevent MASLD complications, linking to cardiovascular risks.

Singapore's Research Leadership in MASLD Innovations

NUS's involvement exemplifies Singapore's higher education prowess. Assoc. Prof. Choi's multi-omics expertise enabled integrative analysis, highlighting Singapore's role in global collaborations. Locally, NUS Medicine's October 2025 study developed fat-like lipid nanoparticles (LNPs) delivering siRNA to silence harmful liver genes, reducing fat by over 70% in mouse models without toxicity.

Duke-NUS Medical School has pioneered: omega-3 lysolipids preventing fat overload (2023), B vitamins reversing advanced fibrosis (2022), and spermidine activating autophagy. These align with the GTPase findings, targeting lipid metabolism and inflammation.NUS LNP study offers precise delivery, complementing GTPase inhibitors.

Challenges in MASLD Management and Fibrosis Detection

Diagnosis relies on biopsies (invasive) or imaging (costly), with FIB-4 scores screening fibrosis risk. In Singapore, high diabetes rates amplify MASLD progression; 2.4% general population has significant fibrosis. Cultural diets rich in sugars exacerbate risks, necessitating public health campaigns.

• Non-invasive biomarkers needed: GTPase signatures could enable early detection.
• Clinical trials lagging: Phase 3 for resmetirom (thyroid agonist) shows promise, but fibrosis-specific drugs scarce.
• Lifestyle barriers: Adherence low despite MOH guidelines.

Universities like NTU are developing AI for risk prediction, enhancing precision medicine.

Implications for Public Health and Future Therapies

This GTPase discovery could spawn drugs inhibiting Rac/Cdc42, halting HSC activation. Combined with Singapore's nanotech (NUS LNPs), targeted therapies loom. Projections: Global MASLD cases to hit 1.27 billion by 2040; Singapore must invest in research to curb healthcare burden.

Stakeholder views: Prof. Kaldis emphasizes collaboration; NUS's Prof. Choi notes omics' power. Future: GTPase modulators in trials, personalized via genomics.

Singapore's Higher Education Ecosystem Driving Liver Research

NUS, NTU, and Duke-NUS form a hub: EXODIAB-like initiatives foster multi-omics. Funding from NRF, A*STAR supports. Case: NUS-Duke-NUS omega-3 study showed Mfsd2a transporter protects via lysolipids, reducing steatosis 50% in models.

Actionable insights: Screen via FIB-4; adopt Mediterranean diet; explore clinical trials.

Stakeholder Perspectives and Real-World Impacts

Patients: Silent killer; 9% HCC risk over 10 years with advanced fibrosis. Experts: MOH pushes screening; AASLD 2025 highlights semaglutide for MASH. Singapore timeline: 1980s rare, now 40%; projected rise with aging.

Economically: S$80M yearly foodborne costs pale vs. MASLD burden. Solutions: University-led trials, policy integration.

Photo by Timo Volz on Unsplash

Future Outlook: From Bench to Bedside in Singapore

Optimism: GTPase drugs 5-10 years away; NUS nanotech accelerates. Outlook: Reduced transplants (Singapore 100+/year), better outcomes. Engage via Rate My Professor for mentors; pursue postdoc roles.

In conclusion, this breakthrough, bolstered by NUS contributions, positions Singapore universities as MASLD leaders, promising fibrosis reversal and healthier futures.